
Yaqing Qie

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7099753/publications.pdf Version: 2024-02-01



YAOING OIF

#	Article	IF	CITATIONS
1	Designing nanomedicine for immuno-oncology. Nature Biomedical Engineering, 2017, 1, .	22.5	178
2	Multivalent bi-specific nanobioconjugate engager for targeted cancer immunotherapy. Nature Nanotechnology, 2017, 12, 763-769.	31.5	136
3	Gut Microbial Metabolites Fuel Host Antibody Responses. Cell Host and Microbe, 2016, 20, 202-214.	11.0	601
4	Surface modification of nanoparticles enables selective evasion of phagocytic clearance by distinct macrophage phenotypes. Scientific Reports, 2016, 6, 26269.	3.3	167
5	362 Priming of the Brain Tumor Microenvironment Enables Improved Nanomedicine Delivery. Neurosurgery, 2016, 63, 207.	1.1	1
6	Protective efficacy of a recombinant BCG secreting antigen 85B/Rv3425 fusion protein against <i>Mycobacterium tuberculosis</i> infection in mice. Human Vaccines and Immunotherapeutics, 2012, 8, 1869-1874.	3.3	5
7	Fusion protein Ag85B-MPT64190–198-Mtb8.4 has higher immunogenicity than Ag85B with capacity to boost BCG-primed immunity against Mycobacterium tuberculosis in mice. Vaccine, 2009, 27, 6179-6185.	3.8	34
8	PPE protein (Rv3425) from DNA segment RD11 of <i>Mycobacterium tuberculosis</i> : a novel immunodominant antigen of <i>Mycobacterium tuberculosis</i> induces humoral and cellular immune responses in mice. Microbiology and Immunology, 2008, 52, 224-230.	1.4	25
9	Trehalose-6-phosphate Phosphatase fromMycobacterium tuberculosisinduces humoral and cellular immune responses. FEMS Immunology and Medical Microbiology, 2007, 49, 68-74.	2.7	12
10	Recombinant BCG coexpressing Ag85B, ESAT-6 and mouse-IFN-Î ³ confers effective protection against <i>Mycobacterium tuberculosis</i> in C57BL/6 mice. FEMS Immunology and Medical Microbiology, 2007, 51, 480-487.	2.7	37